The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK.
GPR55 is an orphan G protein-coupled receptor that may be engaged by some lipid ligands such as lysophosphatidylinositol and cannabinoid-type compounds. Very little is known about its expression pattern and physio-pathological relevance, and its pharmacology and signaling are still rather controversial. Here we analyzed the expression and function of GPR55 in cancer cells. Our data show that GPR55 expression in human tumors from different origins correlates with their aggressiveness. Moreover, GPR55 promotes cancer cell proliferation, both in cell cultures and in xenografted mice, through the overactivation of the extracellular signal-regulated kinase cascade. These findings reveal the importance of GPR55 in human cancer, and suggest that it could constitute a new biomarker and therapeutic target in oncology.
Andradas
C
C
Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University, Madrid, Spain.
Caffarel
M M
MM
Pérez-Gómez
E
E
Salazar
M
M
Lorente
M
M
Velasco
G
G
Guzmán
M
M
Sánchez
C
C
D000818:Animals; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D051379:Mice; D008819:Mice, Nude; D009369:Neoplasms / Q000378:metabolism / Q000473:pathology*; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled / Q000235:genetics / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
C524885:GPR55 protein, human; D043882:Receptors, Cannabinoid; D043562:Receptors, G-Protein-Coupled; D048049:Extracellular Signal-Regulated MAP Kinases
J Soc Gynecol Investig. 2001 Jan-Feb;8(1):1-13
11223350
Brain Res Mol Brain Res. 1999 Feb 5;64(2):193-8
9931487
Br J Pharmacol. 2010 Jun;160(3):762-71
20590578
Nat Rev Cancer. 2007 Feb;7(2):79-94
17251915
Bioorg Med Chem Lett. 2001 Feb 26;11(4):587-90
11229777
Trends Pharmacol Sci. 2009 Mar;30(3):156-63
19233486
Br J Pharmacol. 2010 Feb;159(4):787-96
20136833
Cancer Res. 2006 Jul 1;66(13):6615-21
16818634
J Clin Pathol. 1993 Feb;46(2):189-90
8459046
Proc Natl Acad Sci U S A. 2008 Feb 19;105(7):2699-704
18263732
Pain. 2008 Sep 30;139(1):225-236
18502582
FEBS Lett. 2009 Jun 18;583(12):2071-6
19464294
Nat Rev Mol Cell Biol. 2002 Jan;3(1):30-40
11823796
J Biochem. 2010 May;147(5):671-8
20051382
Cancer Cell. 2006 Apr;9(4):287-300
16616334
FASEB J. 2009 Jan;23(1):183-93
18757503
Cancer Res. 2004 Sep 15;64(18):6503-10
15374961
Trends Pharmacol Sci. 2008 Nov;29(11):582-9
18814923
J Cell Sci. 2008 May 15;121(Pt 10):1704-1717
18445684
Vitam Horm. 2009;81:111-37
19647110
Proc Natl Acad Sci U S A. 2009 Sep 22;106(38):16511-6
19805329
Br J Pharmacol. 2007 Dec;152(7):1092-101
17876302
Biochem Biophys Res Commun. 2007 Nov 3;362(4):928-34
17765871
Br J Pharmacol. 2010 Jun;160(3):604-14
20136841
J Biol Chem. 2009 Oct 23;284(43):29817-27
19723626
J Biol Chem. 2009 May 1;284(18):12328-38
19286662
Eur J Biochem. 1994 Apr 1;221(1):383-9
8168525
J Biochem. 2009 Jan;145(1):13-20
18845565
Oncogene. 1998 May 7;16(18):2357-65
9620553
Clin Cancer Res. 2006 Nov 15;12(22):6598-602
17121877
Oncogene. 2005 Oct 6;24(44):6626-36
16103885